296 results
8-K
EX-99.1
DVAX
Dynavax Technologies Corporation
6 Aug 24
Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates
4:05pm
announced the initiation of a randomized, active-controlled, dose escalation, multicenter Phase 1/2 trial to evaluate the safety, tolerability … and safety data in the second half of 2025, including a comparison of CD4+ T-cells one month after the second of two vaccine doses.
Tdap vaccine program
8-K
EX-99.1
DVAX
Dynavax Technologies Corporation
8 May 24
Dynavax Reports First Quarter 2024 Financial Results
4:05pm
the safety, tolerability, and immunogenicity of Z-1018 compared to Shingrix® in approximately 440 healthy adults aged 50 to 69.
Dynavax plans to initiate … the Phase 1/2 trial in the second quarter of 2024 and expects to report top line immunogenicity and safety data in the second half of 2025.
Tdap
8-K
EX-99.1
pw8b ae1muiqz4h7z
22 Feb 24
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results
4:05pm
8-K
EX-99.2
6tpj4adco8
8 Jan 24
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
9:05am
8-K
EX-99.1
kaun inu4tc2lkh2k4
8 Jan 24
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
9:05am
8-K
EX-99.1
jtsqouefk4l1x
2 Nov 23
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
4:10pm
8-K
EX-99.1
e4michvw ojew3
3 Aug 23
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
4:11pm
8-K
EX-99.1
tnzczdx
2 May 23
Dynavax Reports First Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
4qio6qxkf ajlwlhofe
3 Nov 22
Dynavax Reports Third Quarter 2022 Financial Results
4:10pm